Ban on oral formulations of nimesulide over 100 mg, Pg16

Key Highlights:

• The Union Health Ministry has banned oral formulations of nimesulide above 100 mg in immediate release form.
• The ban was issued due to concerns over potential liver toxicity associated with higher doses of nimesulide.
• The ban is enforced under Section 26A of the Drugs and Cosmetics Act, 1940, following consultation with the Drugs Technical Advisory Board.
• Formulations below 100 mg or in sustained/extended release forms, and non-oral formulations are exempt from the ban.

Detailed Insights:

• Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) used for pain relief, anti-inflammatory, and fever-reducing effects.
• It is typically prescribed as a second-line treatment for short-term use due to concerns about potential liver toxicity.
• The government's notification cites the availability of safer alternatives as a reason for banning higher doses of nimesulide.
• Fixed-drug combinations, including nimesulide, are popular due to their therapeutic effectiveness and cost benefits.
• Nimesulide is approved for treating acute pain, symptomatic relief in painful osteoarthritis, and primary dysmenorrhea.

Key Concepts Involved:

• Nimesulide: A non-steroidal anti-inflammatory drug (NSAID) used to treat pain, inflammation, and fever.
• Liver Toxicity: Liver damage caused by exposure to a drug or other chemical substance.
• Drugs and Cosmetics Act, 1940: Indian law that regulates the import, manufacture, distribution, and sale of drugs and cosmetics.